Vaccine Design
At Biointelix, we provide advanced vaccine design solutions powered by computational biology, structural modeling, and immunoinformatics. In particular, our approach focuses on analyzing the antigen sequence, structure, and function to identify the most exposed and immune-accessible regions. As a result, these insights guide the selection of epitopes and the construction of multi-epitope vaccines. Ultimately, the designed constructs are optimized for immunogenicity, safety, and efficacy.
Computational Vaccine Design Workflow
1. Antigen Analysis for Vaccine design
We analyze the sequence and 3D structure of the target antigen to determine which regions are exposed to the immune system. In particular, since membrane-embedded or buried protein regions are hidden from immune recognition, we therefore focus on surface-exposed domains most likely to trigger protective immunity.
2. Epitope Identification
Using state-of-the-art prediction tools, we identify:
- B-cell epitopes → recognized by antibodies
- Cytotoxic T lymphocyte (CTL) epitopes → stimulate cellular immunity
- Helper T lymphocyte (HTL) epitopes → support adaptive immune responses
As a result, only epitopes that are accessible and relevant in the native antigen structure are selected.
3. Multi-Epitope Vaccine Construction
Furthermore, we design a vaccine construct by connecting epitopes with flexible linkers, ensuring proper folding and immune recognition. In addition, an adjuvant or carrier domain is incorporated to enhance the immune response.
The construct includes:
- Adjuvant or carrier protein
- Top B-cell, CTL, and HTL epitopes
- Stability-preserving linkers
4. Structural and Functional Simulation
We model the 3D structure of the vaccine construct and perform immune response simulations to predict:
- Antibody production
- T-cell activation
- Cytokine release
This step helps estimate how the vaccine may behave in a real immune system.
Structural Schematic of the Multi-Epitope Vaccine Construct Design with Adjuvant and Linkers
This figure illustrates the structural organization of a multi-epitope vaccine construct. In particular, the design includes an adjuvant or carrier region, followed by B-cell, CTL, and HTL epitopes. These epitopes are interconnected by suitable linkers, ensuring proper separation and flexibility, and are ultimately fused to the adjuvant/carrier domain to enhance immunogenicity.
5. Epitope Exposure Validation
Furthermore, we verify that selected epitopes remain exposed in the 3D native antigen, maximizing recognition by antibodies and immune receptors.
6. Immunogenicity and Safety Profiling
In addition, the construct is assessed for:
- Immunogenicity potential
- Allergenicity risk
- Toxicity predictions
This ensures that the designed vaccine is not only effective but also safe.
7. Alternative Conformations
When possible, we explore alternative conformational structures of the designed vaccine to improve stability and antigenicity.
8. Translational Pathway
Our computational pipeline provides strong candidates for experimental validation. For example, in preclinical models, the designed vaccines can be tested for their ability to generate antibodies that recognize the native antigen.
Why Biointelix for Vaccine Design?
- Expertise in Antigen Analysis: Focused on exposed, immune-accessible regions.
- Comprehensive Epitope Prediction: B-cell, CTL, and HTL epitopes included.
- Advanced Structural Modeling: 3D analysis for accuracy and precision.
- Immune System Simulation: Predicts real-world immune responses.
- Safety First: Immunogenicity, allergenicity, and toxicity checks.
- Accelerated Discovery: Reduce time and cost before moving to the lab.
Applications
- Infectious disease vaccines
- Cancer vaccine design
- Peptide-based and subunit vaccines
- Personalized immunotherapy vaccines
Partner With Us
At Biointelix, our computational vaccine design platform bridges the gap between in silico prediction and experimental validation. As a result, it helps researchers, biotech startups, and pharmaceutical companies accelerate their vaccine development pipelines.
Contact us today to discuss how our vaccine design expertise can support your next breakthrough.